Lifeward Closes Oramed Strategic Partnership, Secures $10M Capital Infusion
Summary
Lifeward Ltd. has successfully closed its strategic partnership with Oramed Pharmaceuticals, acquiring Oramed's clinical-stage Protein Oral Delivery (POD™) technology. This transaction immediately provides Lifeward with $10 million in capital, part of an agreement for up to $47 million, which is a highly material capital infusion for a company with a market capitalization of approximately $10 million. This closing finalizes the strategic deal that shareholders approved on March 13th, which was previously highlighted as a "critical, highly dilutive strategic financing deal" in Lifeward's recent 10-K that also included a going concern warning. The partnership is expected to diversify Lifeward into a biomedical innovation company with a clear path to profitability, significantly de-risking the company's financial position and future outlook. Investors will now watch for execution on the new strategy and the impact of the capital on operations and product development.
At the time of this announcement, LFWD was trading at $6.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10M. The 52-week trading range was $4.14 to $23.04. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.